Although Interferon plus bevacizumab have demonstrated similar impact than oral agents as a first-line therapy for metastatic RCC, oral monotherapy with a TK inhibitor has become the “de facto” standard of care in this situation. Here, TKT is linked to renal cell adenocarcinoma.